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Abstracts / Osteoarthritis and Cartilage 20 (2012) S10–S53S34subregions showing worsening (Table 1). No signiﬁcant associations
were found for the lateral TF and PF compartment and respective plates
cross-sectionally or longitudinally.
Conclusions:When compared to controls, knees that receive TKR have
increased odds of presence of large BMLs in the medial femur and/or
tibia at the time point prior TKR, while the odds for large BMLs in the
lateral TFJ or in the PFJ are not increased. Further, knees that receive TKR
have increased odds for worsening of BML size in 3 subregions in the
medial TF compartment. This work provides evidence of the clinical
predictive validity of BMLs and further justiﬁcation for their use as
outcomes in disease modifying OA trialsFigure 1. 12 Month logistic models of pain. a) ROC plot of the pain in bed model b) ROC
model of the max pain predicting model.
Figure 2. Area under the curve of the ROC of WOMAC pain predicting models with
their 95% Conﬁdence intervals.48
STRUCTURAL BIOMARKERS PREDICT ONSET OF KNEE PAIN: DATA
FROM THE OSTEOARTHRITIS INITIATIVE
J.G. Tamez-Pena 1,2, P.C. Gonzalez 2, E.H. Schreyer 2,
S.M. Totterman 2. 1 Tecnologico de Monterrey, Escuala de Med.,
Monterrey, Mexico; 2Qmetrics Technologies, Rochester, NY, USA
Purpose: Joint pain is the most signiﬁcant symptom of OA. However,
morphologic changes in bones and cartilage may precede onset of pain.
The purpose of this study was to evaluate in a case-control setting
which morphological changes predict the development of different
subcategories of knee pain at 12, 24 or 36 months in the future.
Methods: Osteoarthritis initiative (OAI) data sets were mined to ﬁnd
subjects whose right knee was free of joint pain at baseline but had
a WOMAC pain score of 5 or greater at the 36 month observation. 61
Subjects from the OAI Incidence Cohort met the inclusion criteria. A
control cohort was created bymatching age, BMI, and gender of each case
subject to an incident cohort subjectwhose36monthWOMACpain scores
were zero. The 122 subjects’ 3DDESSWEMRI series [1] were analyzed for
cartilage thickness and for bone-cartilage interface curvature and signal
contrast of the entire femur and tibia (Qmetrics, Rochester, NY). Thickness
measurementswere normalizedusing a standard reference atlas. Receiver
operating characteristic curves (ROC) and the area under the curve (AUC)
of the ROC were used to assess the potential of the quantitative
measurements as predictors of the 12, 24 and 36-month WOMAC pain
scores for following sub-categories: sitting, walking, lying in bed, climbing
stairs and standing pain. Each non-zero score was considered a positive
response. The quantitative measurements that best predicted future pain
were used to build a logistic regression model of the observed pain. The
strength of model was then characterized by ROC analysis.
Results: The age, gender and BMI of the case subjects matched to
control subjects with no statistical differences between the groups. TheROC analysis identiﬁed several morphological variables (Standard
deviation of cartilage thickness, and the presence of large thin areas of
medial cartilage and in the lateral femur condyle) which weakly pre-
dicted future pain (AUC<0.62). The subcategories analysis shows that
there is strong preference to predict bed pain at 12 month (AUC<0.73).
24-month pain and 36-month pain were harder to predict based on the
baseline observations.
Using the pain predicting variables, unconditional logistic models were
used to predict the pain. Figure 1a) shows the model ROC analysis of
pain in bed at 12 month, and 1b) the 12-month max pain model ROC.
Figure 2 shows a plot of the different AUC for all models predicting
future pain. AUC at 12-month models were better than 24 or 36-month
models. Pain in bed was more predictable and walking pain was harder
to predict using the measured variables.Conclusions: Quantitative measurements of bone and cartilage
morphology can predict onset of knee pain. The predictive power of
those descriptors can be enhanced using a multivariate model of pain
with good sensitivity and speciﬁcity especially when predicting the
onset of pain within 12 months. Furthermore, these models can be
viewed as risk factors for developing chronic knee pain; therefore, they
may be helpful in the development and test of OA therapies.
References: Tamez-Pena J. et al. “Atlas based method for the automated
segmentation and quantiﬁcation of knee features: Data from the oste-
oarthritis initiative” IEEE, ISBI, pp 1484 - 1487, 2011
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INFLAMMATORY GENOMIC AND PLASMA BIOMARKERS PREDICT
PROGRESSION OF SYMPTOMATIC KNEE OA (SKOA)
M. Attur 1, A. Statnikov 2, C.F. Aliferis 2, Z. Li 2, S. Krasnokutsky 1,
J. Samuels 1, J.D. Greenberg 1, J. Patel 1, C. Oh 1, Q.A. Lu 3, R. Ramirez 3,
J. Todd 3, S.B. Abramson 1. 1NYU Hosp. for Joint Diseases, New York, NY,
USA; 2Ctr. for Hlth.Informatics and Bioinformatics, New York, NY, USA;
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Purpose: OA is considered a local joint disease, with increasing
recognition of the involvement of cartilage, bone and synovium. We
Table 2
Predictors of JSN dichotomized at >0.2 mm/24 months
Predictor Area under ROC
curve (AUC)
p-value q-value (FDR)
Plasma tMMP-9 0.66 0.002 0.011
Plasma IL-1Ra 0.63 0.017 0.026
PBL COX2 gene expression 0.65 0.005 0.011
Multivariate predictive model 0.74 <0.001 _
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and IL-1b, are produced by OA joint tissues, where they may
contribute to disease pathogenesis. In the current studies we
examined whether inﬂammatory events occurring within joint
tissues could be reﬂected outside the joint in the plasma and
peripheral blood leukocytes (PBLs) of patients with OA.
Methods: We recruited 178 SKOA patients (mean age 63.09  10.3,
mean BMI 26.5  3.6) as part of an NIH-funded 24 month
prospective study. 144 patients completed the study and had x-ray
and blood samples at baseline and 24 months. Standardized semi-
ﬂexed radiographs were scored for overall KL grade and joint space
width (JSW) by the same radiologist. Plasma samples were
assayed for MMP2, 9, IL-1b, TNFa, VEGF and IL-1Ra using the
highly sensitive Erenna Immunoassay system (Singulex, Inc). PBL
gene expression of COX-2, IL-1b and TNFa was determined by gene
array.
Results: Using support vector machine methodology, we con-
structed a combinatorial biomarker of OA based on microarray
data. Among these probe sets representing PGE2 synthase and
COX-2 could classify the case vs. control with 0.83 mean AUC (95%
CI 0.72- 0.95) (AUC: area under ROC curve), as estimated by 10-fold
cross-validation procedure. Further cluster analysis also revealed
two distinct subclasses among these OA patients: those (OA1) with
increased expression (>4-fold) of inﬂammatory genes (e.g, IL-1b,
COX-2) compared to controls and those OA patients (OA2) with
expression comparable to controls. Overexpression of
inﬂammatory genes were validated using QPCR (p<0.0001). Based
on QPCR, we dichotomized OA patients based on median
expression level of IL-1b, COX-2, and TNFa; Table 1 shows that
patients whose PBL exhibited an inﬂammatory phenotype (OAIL-1,
OACOX-2, or OATNFa) were at higher risk for rapid disease progres-
sion (JSN). In baseline association studies, patients in the OAIL-1
group also exhibited: a) higher WOMAC pain, stiffness and
decreased physical function (p<0.0001), b) higher VAS pain
(p<0.001) than OAnl group. To determine whether OA PBLs were
“primed”, we measured PGE2 production by whole blood PBL
cultured (24h) ex vivo. PGE2 in controls did not change, while
levels in OA patients increased 300% over baseline (p<0.01). Of
interest, the mean plasma PGE2 levels in OA patients was two-fold
higher than in controls (72  33 vs. 163  64 pg/ml, p¼0.001). We
next analyzed the 144 completer patients with regard to
radiographic progression by JSN. We assessed the following 10
clinical, protein, and genomic predictors: VAS pain, WOMAC score,
plasma PGE2, tMMP-9, VEGF, IL-1Ra, PBL IL-1b expression, TNFa
and COX2 expression. Among these, three biomarkers (plasma
tMMP-9 and IL-1ra; and PBL COX-2 expression) univariately were
signiﬁcant predictors of JSN dichotomized at >0.2 mm/24 months,
according to Delong's test for comparing areas under ROC curve at
0.05 a-level. When these three statistically signiﬁcant
predictors were combined into a multivariate predictive model
using kernel ridge regression, the resulting predictivity of JSN
increased to 0.74 AUC (95% CI [0.63; 0.84] AUC, p ¼ <0.001)
[Table 2].
Conclusions:. The data indicate that inﬂammatory events
within joint tissues of patients with SKOA are reported in
peripheral blood. This includes increased inﬂammatory
mediator gene expression (COX-2, IL-1b and TNFa) by PBLs in
a subset of patients with SKOA, which identiﬁes a cohort of patients
with increased pain who are at increased risk for disease
progression. These transcriptome and plasma protein/lipid signals
of local joint inﬂammation merit further study as potential
prognostic biomarkers for OA disease progression.Table 1
PBL IL-1, COX-2, and TNFa over-expression (QPCR) are associated with increased joint sp
JSW (mm) knee medial IL-1 (PBL mRNA) COX-2 (PB
OAIL-1 (n¼73) OAnl (n¼71) p value OACOX-2 (n
baseline 3.44 (1.80) 3.07 (1.71) 0.15 3.30 (1.89)
24 month 2.89 (1.83) 2.99 (1.72) 0.74 2.78 (1.83)
JSN (mm) 0.55 (0.93) 0.07 (1.01) 0.007 0.52 (1.03)50
SYNERGISTIC CHONDROPROTECTIVE EFFECT OF CHONDROTIN
SULFATE AND GLUCOSAMINE: A PHARMACOPROTEOMIC STUDY.
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Purpose: To assess the synergistic chondroprotective effect of chon-
droitin sulphate (CS) and glucosamine hydrochloride (GH) in modifying
cartilage extracellular matrix metabolism by chondrocytes secreted
proteins analysis using iTRAQ technique.
Methods: Cartilage obtained from patients undergoing joint
replacement was provided by the Tissue Bank and the Autopsy
Service at CHU A Coruña. The study was approved by the local Ethics
Committee. Chondrocytes released from osteoarthritic (OA) cartilage
by enzymatic digestion were recovered and cultured in basic DMEM
supplemented with antibiotics and 10% FBS. When conﬂuence was
reached, OA chondrocytes were treated with CS alone and in
combination with GH (both at 200mg/mL). 48 hours later, condi-
tioned media were collected and their proteins were concentrated
and quantiﬁed. Trypsin digestion and labelling with isobaric tags
using iTRAQ reagents were performed. Then, peptides from the four
conditions (untreated, CS-treated, GH-treated, and CS+GH-treated)
were mixed, separated and analyzed by nanoscale reversed-phase
liquid chromatography coupled to mass spectrometry (nLC-MALDI-
MS/MS). The identiﬁcation and quantiﬁcation of proteins (by calcu-
lating the different iTRAQ tags intensities for each peptide) was
carried out with Protein Pilot 3.0 software. CS and GH were provided
from Bioibérica, S.A. (Barcelona, Spain).
Results: Database search (UniprotKB/Swissprot) allowed us the iden-
tiﬁcation of 143 different proteins in the OA chondrocyte secretome. For
biological and functional analysis we considered only those proteins
with a probability score higher than 95%, and a ratio 1.2 or 0.8.
Finally, 17 secreted proteins presented statistically signiﬁcant differ-
ences (p0.05) between untreated and treated samples: 13 were
increased and 4 decreased (see table 1). CS alone modulated 3 proteins,
while in combination with GH modulated 7 proteins. Most of the
altered proteins are cartilage ECM components (59%), such as collagens
and proteoglycans. Interestingly, we found increased LTBP2, thus sug-
gesting a possible effect of the combined formulation in inhibiting
osteophyte formation and ﬁbrosis induced by high amounts of TGF-beta
into OA joints.
Conclusions: We have carried out the ﬁrst pharmacoproteomic study
based on peptides labelling with 4 isobaric tags (iTRAQ) to study the
effect of CS, alone and in combination with GH, on chondrocytes
secretome. Our ﬁndings conﬁrm the potential synergistic chon-
droprotective effect of chondrotin sulfate and glucosamine
hydrochloride.ace narrowing (JSW) at 24 months. Values are expressed as mean (SD).
L mRNA) TNFa (PBL mRNA)
¼74) OAnl (n¼70) p value OATNFa(n¼74) OAnl (n¼70) p value
3.2 (1.63) 0.35 3.20 (1.89) 3.31 (1.64) 0.7097
3.11 (1.7) 0.54 2.61 (1.87) 3.29 (1.60) 0.0198
0.091 (0.92) 0.007 0.59 (0.98) 0.02 (0.93) 0.0004
